Our study, using amplicon-based technology, demonstrated the presence of over 80% of NFM mutations detected in eight genes: CTNNB1, PIK3CA, PTEN, ATM, KRAS, PTPN11, TP53 and JAK3. Moreover, TP53, KDR, KIT, ERBB4 and EGFR genes were found to have more than 20 mutations in over 50% of primary DLBCL CNS patients. This evidence concerns the gene KIT and diffuse large B-cell lymphoma.